Regulatory clampdowns, increased competition and channel consolidation in the US have led to a drop of 30% — one of the worst — in earnings of US-focused Indian pharma companies in FY18. But the good news is there are signs of recovery with a strong double-digit growth expected in FY19.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/2JViIHW